Pesenti; Enrico

Patent Applications and Registrations

Patent applications and USPTO patent grants for Pesenti; Enrico.The latest application filed is for "therapeutic combination comprising a parp-1 inhibitor and an anti-neoplastic agent".

Company Profile

0.14.12

Pesenti; Enrico - Parabiago IT
Pesenti; Enrico - Parabiago (MI) IT
Pesenti, Enrico - Milan IT
Pesenti; Enrico - Cologno Monzese IT

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Therapeutic combination comprising a Cdc7 inhibitor and an anti-neoplastic agent Grant 9,119,877 - Ballinari , et al. September 1, 2	2015-09-01
Use of CDK inhibitor for the treatment of glioma Grant 8,946,226 - Ciomei , et al. February 3, 2	2015-02-03
Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent Grant 8,927,530 - Valsasina , et al. January 6, 2	2015-01-06
Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent Grant 8,518,930 - Ciomei , et al. August 27, 2	2013-08-27
Therapeutic Combination Comprising A Parp-1 Inhibitor And An Anti-neoplastic Agent App 20130129841 - Ciavolella; Antonella ; et al.	2013-05-23
Therapeutic Combination Comprising A Cdc7 Inhibitor And An Anti-neoplastic Agent App 20120276093 - Ballinari; Dario ; et al.	2012-11-01
Therapeutic Combination Comprising A Plk1 Inhibitor And An Antineoplastic Agent App 20120114641 - Valsasina; Barbara ; et al.	2012-05-10
Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic Grant 8,084,027 - Mercurio , et al. December 27, 2	2011-12-27
Therapeutic Combination Comprising A Cdks Inhibitor And An Antineoplastic Agent App 20110312909 - Ciomei; Marina ; et al.	2011-12-22
Use Of Cdk Inhibitor For The Treatment Of Glioma App 20110190311 - Ciomei; Marina ; et al.	2011-08-04
Therapeutic Combination Comprising An Aurora Kinase Inhibitor And Antiproliferative Agents App 20110129467 - Pesenti; Enrico ; et al.	2011-06-02
Therapeutic Combination Comprising An Aurora Kinase Inhibitor And An Antineoplastic Agent App 20110117212 - Pesenti; Enrico ; et al.	2011-05-19
Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib App 20100022553 - Moll; Jurgen ; et al.	2010-01-28
Antitumor Combination Comprising Substituted Acryloyl Distamycin Derivatives and Antibodies Inhibiting Growth Factors or Their Receptors App 20090074757 - Pesenti; Enrico ; et al.	2009-03-19
Combinations Comprising a CDK Inhibitor and a Growth Factor Antibody or Anti-Mitotic App 20090017025 - Mercurio; Ciro ; et al.	2009-01-15
Fluoro linkers and their use as linkers for enzyme-activated drug conjugates App 20050107543 - Angelucci, Francesco ; et al.	2005-05-19
Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents Grant 6,165,980 - Cozzi , et al. December 26, 2	2000-12-26
Distamycin A analogues as antitumour or antiviral agents Grant 5,753,629 - Beria , et al. May 19, 1	1998-05-19
Polymer-bound paclitaxel derivatives Grant 5,719,265 - Mongelli , et al. February 17, 1	1998-02-17
Polymer-bound paclitaxel derivatives Grant 5,473,055 - Mongelli , et al. December 5, 1	1995-12-05
Polymer-bound paclitaxel derivatives Grant 5,362,831 - Mongelli , et al. November 8, 1	1994-11-08

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.